Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Kou T, Kanai M, Yamamoto M, Xue P, Mori Y, Kudo Y, Kurita A, Uza N, Kodama Y, Asada M, Kawaguchi M, Masui T, Mizumoto M, Yazumi S, Matsumoto S, Takaori K, Morita S, Muto M, Uemoto S, Chiba T. Kou T, et al. Among authors: mizumoto m. Int J Clin Oncol. 2016 Feb;21(1):118-25. doi: 10.1007/s10147-015-0864-x. Epub 2015 Jun 28. Int J Clin Oncol. 2016. PMID: 26123314
A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement.
Masui T, Takaori K, Anazawa T, Sato A, Nakano K, Uchida Y, Yogo A, Goto Y, Matsumoto S, Kodama Y, Kanai M, Isoda H, Mizumoto M, Kawaguchi Y, Shibuya K, Itasaka S, Uemoto S. Masui T, et al. Among authors: mizumoto m. Anticancer Res. 2017 Dec;37(12):7023-7030. doi: 10.21873/anticanres.12172. Anticancer Res. 2017. PMID: 29187490
Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution.
Masui T, Nagai K, Anazawa T, Sato A, Uchida Y, Nakano K, Yogo A, Kaneda A, Nakamura N, Yoshimura M, Mizowaki T, Uza N, Fukuda A, Matsumoto S, Kanai M, Isoda H, Mizumoto M, Seo S, Hata K, Taura K, Kawaguchi Y, Takaori K, Uemoto S, Hatano E. Masui T, et al. Among authors: mizumoto m. BMC Cancer. 2022 Jan 29;22(1):119. doi: 10.1186/s12885-022-09244-6. BMC Cancer. 2022. PMID: 35093003 Free PMC article. Clinical Trial.
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, Okajima H, Kaido T, Minamiguchi S, Uemoto S. Kitajima T, et al. Among authors: mizumoto m. Clin J Gastroenterol. 2015 Oct;8(5):300-5. doi: 10.1007/s12328-015-0594-7. Epub 2015 Aug 7. Clin J Gastroenterol. 2015. PMID: 26249525
291 results